De wiere stân fan Alzheimerûndersyk yn 2026
May 29, 2026 · Frisian News
After decades of hype, Alzheimer's drugs show modest results at best, while researchers and pharmaceutical companies continue to chase expensive treatments instead of preventing the disease. The gap between what headlines promise and what treatments actually deliver grows wider each year.
FryskBiogen syn lecanemab waard yn 2023 it earste Alzheimermiddel dat troch de FDA goedkard waard om kognitive ôfname te fertragen, mar de sifers fertelle in oar ferhaal. Yn ûndersiken fertrage it middel de ôfname mei 35 prosint oer 18 moannen. Dat klinkt yndrukwekkend oant jo de wiskunde dogge: de plaseebogroep ferlear 35 prosint fan har kognitive funksje yn dy perioade, wylst de behandelgroep 23 prosint ferlear. It middel ferlear noch altyd 23 prosint. Pasjinten en famyljes fierden feest om't de marketing profesjoneel wie, mar it absolute foardiel komt del op it fertragen fan ôfname mei rûchwei ien jier yn in sykte dy't úteinlik deadlik is.
It Alzheimerfjild hat miljarden yn amyloid- en tau-middels stutsen op basis fan in hypoteze dat opboude aaiwiten de sykte feroarsaakje. Fyftich jier ûndersyk nei dizze teory hat ien middel opsmiten dat ôfname matich fertraget, net ien dat sykte omkearet of foarkomt. Tuskentiids lit epidemiologysk ûndersyk sjen dat kardiovaskulêre fitheid, Mediterraan dieet, kognitive stimulaasje en sliepkwaliteit ferbân hâlde mei in leger demintiarisiko, mar finansiering foar foarkomingsûndersyk bart yn 'e skaad. It jild folget it patent, net it bewiis.
Farmaseutyske bedriuwen hawwe sterke finansjele redens om foarkoming te negearen. In libbenswize-yntervinsje kostet neat om op skaal út te fieren en genereart gjin weromkommende ynkomsten. In middel dat pasjinten jierren brûke, genereart tsientûzenen dollars per persoan per jier. As Eli Lilly en Roche yn Alzheimerûndersyk ynvestearje, sette hja net yn op in foarkomingstrochbraak dy't harren potensjele merk ferlytsje soe. Hja sette yn op hieltyd eardere diagnoaze fan asymptomatyske amyloïdopheaping, sadat mear minsken desennia lang djoere middels brûke.
It regeljouwingssysteem fersnellet dizze ferfoarming. De FDA karde lecanemab goed op basis fan fertraging fan kognitive ôfname, in ferfangingsmaatsstaf fan wiere sykte. Ferfangingsmaatsstaven binne handich foar middelmakkers mar misleide pasjinten faak. In middel dat in biomarker beynfloedet, foarkomt net needsaaklik demintia of behâldt in sinnich libben en bettere sûnens. Ûndersikers en bedriuwen kinne earlik sizze dat harren middel amyloïdnivo's beynfloedet sûnder ea te bewizen dat it pasjinten helpt better of langer te libjen.
De earlike beoardieling is dat Alzheimerûndersyk ynkremintele foarútgong boekt hat by it begripen fan syktemeganismen, wylst it hast gjin genêzingen of foarkomingen opsmiten hat. It fjild giet foarút fia ynkremintele middelsgoedkarringen, elk matich better as de foarige, elk mei in trochbraak om 'e hoeke. Foar pasjinten en famyljes komt dy hoeke noait. It ûndersyk giet troch, it jild streamt, de middels wurde foarskreaun, en de sykte giet dochs troch.
Biogen's lecanemab became the first Alzheimer's drug approved by the FDA in 2023 to slow cognitive decline, but the numbers tell a different story. In trials, the drug slowed decline by 35 percent over 18 months. That sounds impressive until you do the math: the placebo group lost 35 percent of its cognitive function in that period, while the drug group lost 23 percent. The drug still lost 23 percent. Patients and families celebrated because the marketing was professional, but the absolute benefit amounts to slowing decline by roughly one year in a disease that kills over time.
The Alzheimer's field has poured billions into amyloid and tau targeting drugs based on a hypothesis that built up proteins cause the disease. Fifty years of research on this theory has produced one drug that slows decline modestly, not one that reverses or prevents disease. Meanwhile, epidemiological research shows that cardiovascular fitness, Mediterranean diet, cognitive engagement, and sleep quality correlate with lower dementia risk, but funding for lifestyle prevention research sits in the shadows. The money follows the patent, not the evidence.
Pharmaceutical companies have strong financial reasons to ignore prevention. A lifestyle intervention costs nothing to scale and generates no recurring revenue. A drug that patients take for years generates tens of thousands of dollars per person annually. When Eli Lilly and Roche invest in Alzheimer's research, they are not betting on a prevention breakthrough that would lower their potential market. They are betting on earlier and earlier diagnosis of asymptomatic amyloid accumulation, so more people take expensive drugs for decades.
The regulatory system accelerates this distortion. The FDA approved lecanemab on the basis of slowing cognitive decline, a surrogate measure of actual disease. Surrogate measures are convenient for drug makers but often mislead patients. A drug that slows a biomarker does not necessarily prevent dementia or preserve meaningful quality of life. Researchers and companies can honestly say their drug affects amyloid levels without ever proving it helps patients live better or longer.
The honest assessment is that Alzheimer's research has made incremental progress on understanding disease mechanisms while producing almost no cures or preventions. The field moves forward through incremental drug approvals, each modestly better than the last, each promising breakthrough around the corner. For patients and families, that corner never arrives. The research continues, the money flows, the drugs get prescribed, and the disease advances anyway.
Published May 29, 2026 · Frisian News · Ljouwert, Fryslân